Oragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral Mucositis March 23, 2018
Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile March 19, 2018
Oragenics Announces Closing of $3.3 Million Preferred Stock Private Placement and $3.4 Million Debt Conversion into Equity November 9, 2017
Oragenics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference September 6, 2017
Oragenics Announces Completion of Second Closing of $3.0 Million Preferred Stock Private Placement July 26, 2017
